Bioentrepreneur

The East provides increasing opportunities for biotech companies seeking to optimize product development and accelerate time to market. But any undertaking in China or India requires close scrutiny of the risks.

Getting a second date with a venture capitalist requires good planning and an ability to read between the lines.

An analysis of recent trends in licensing and financing transactions that affect early to mid-stage life science companies and their investors.

An analysis of recent trends in intellectual property that affect early- to mid-stage life sciences companies and their investors.

One year after its passage, California's embryonic stem cell research funding initiative remains a mixed blessing for biotech startups.

Are reverse mergers the answer to biotech's capital crunch? This IPO alternative, in which a viable company goes public through a defunct 'shell' company that no longer has operations, is becoming increasingly popular. But it pays to understand the downside, too.

Canadian citizens, the government and its entrepreneurs are all keen on biotech. Startup incentives, government supports and talent are not hard to find in Canada, but the message isn't getting out. Boosters think they know why and have a solution.

Specialized academic training, seminars and mentoring programs are slowly emerging to woo and equip female biotech entrepreneurs.

Nanobiotech entrepreneurs learned the hard way that there is such a thing as pushing so-called exotic or emerging technologies too hard with investors. Biotech entrepreneurs could learn a thing or two from their experience.

Will 2006 bring a new set of expectations about M&A among entrepreneurs?

China's biotech ambitions rest squarely upon the shoulders of Taiwan. Thus far, the tiny island is proving that it is up to the task.

Young biotech startups can benefit hugely from the US National Institutes of Health (NIH), not least because of the agency's non-dilutive funding, guidance, and opportunities for collaboration. Increasingly, however, there is a fair bit of misunderstanding about what the NIH can and cannot do for a biotech entrepreneur.

Venture capitalists and angels are pulling back from seed rounds, just as biotech startups need more money than ever to get off the ground.

In recent years, a number of universities have created graduate degrees in biotech and business. Although it's still too early to measure their value, it appears that they are already inspiring debate and some startup activity.

The UK government is looking for a few good US biotech entrepreneurs.

New York City is crowing about the long-awaited arrival of a new biotech park, but the city will have to overcome its image as a financial and fashion capital before it captures the interest of biotech startups.

You've heard enough bragging about the great licensing successes of your colleagues. But for each successful deal, there is at least one total disaster that they try to forget. It's time to pull back the curtain and talk about some truly lousy deals.

As biopharmaceutical companies are pushed up the pipeline to find the best licensing deals, some small biotechs are starting to command more money at an earlier stage in their research.

The government of Chile turns to a consortium of business leaders and academics to bolster its biotech prospects.

The US National Cancer Institute has completed its funding for nanobiotech projects, but the debate about its value to startups lingers.